The global Transfusion Dependent Thalassaemia Management Market is expected to garner a market value of US$ 10 Million in 2023 and is expected to accumulate a market value of US$ 17.91 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Transfusion Dependent Thalassaemia Management registered a CAGR of 4% in the historical period 2018 to 2022.
Studies state that Thalassemia affects approximately 4.4 out of every 10,000 live births throughout the world. To enable effective Transfusion Dependent Thalassaemia Management, market players are effectively leveraging strategic partnerships with major pharmaceutical corporations or research institutes, mergers & acquisitions and capacity expansion initiatives.
Request a Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16470
In November 2022, the Centers for Disease Control and Prevention (CDC) launched a Thalassemia Healthcare Provider Resource Toolkit. This free toolkit is filled with the free resources for providers caring for people living with thalassemia. It includes Continuing Medical Education Offerings and Webinars, Scientific Articles and Features, CDC Activities Related to Transfusion Complications in Thalassemia, Resources on Newborn Screening, Thalassemia Treatment Centers, Resources for Thalassemia Care, Treatment, and Management and so on.
North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. Furthermore, government initiatives and increase in the number of research partnerships are boosting the market growth across North America.
Key Takeaways from the Market Study
- From 2018 to 2022, the Transfusion Dependent Thalassaemia Management market grew at a CAGR of 4%.
- The global Transfusion Dependent Thalassaemia Management market is expected to grow with a 6% CAGR during 2023 to 2033.
- As of 2033, the Transfusion Dependent Thalassaemia Management Market is expected to reach US$ 17.91 Million
- According to the FMI analysis, hospitals account for the largest market share.
- North America is expected to possess 25% market share for the Transfusion Dependent Thalassaemia Management market.
- The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Transfusion Dependent Thalassaemia Management.” says an FMI analyst
Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-16470
Market Competition
Key players in the Transfusion Dependent Thalassaemia Management market Celgene Corporation, BlueBird Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Sangamo Therapeutics, Orchard Therapeutics, CRISPR Therapeutics, and DisperSol Technologies among other global players.
- In August 2022, the US Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.
Key Segments Profiled in the Transfusion Dependent Thalassaemia Management Industry Survey
Therapy:
- Iron Chelating Drugs
- Erythroid Maturation Agents
- Stem Cell Therapy
- Others
End-User:
- Hospital
- Homecare
- Specialty Clinics
- Others
Buy Now@ https://www.futuremarketinsights.com/checkout/16470
About the Healthcare Division at Future Market Insights
The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
